CN105078998B - 抑制移植物抗宿主病的PKCθ的小分子抑制剂 - Google Patents
抑制移植物抗宿主病的PKCθ的小分子抑制剂 Download PDFInfo
- Publication number
- CN105078998B CN105078998B CN201510471935.2A CN201510471935A CN105078998B CN 105078998 B CN105078998 B CN 105078998B CN 201510471935 A CN201510471935 A CN 201510471935A CN 105078998 B CN105078998 B CN 105078998B
- Authority
- CN
- China
- Prior art keywords
- pkc
- cell
- car
- gvhd
- tcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510471935.2A CN105078998B (zh) | 2015-08-05 | 2015-08-05 | 抑制移植物抗宿主病的PKCθ的小分子抑制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510471935.2A CN105078998B (zh) | 2015-08-05 | 2015-08-05 | 抑制移植物抗宿主病的PKCθ的小分子抑制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105078998A CN105078998A (zh) | 2015-11-25 |
CN105078998B true CN105078998B (zh) | 2017-09-19 |
Family
ID=54560930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510471935.2A Active CN105078998B (zh) | 2015-08-05 | 2015-08-05 | 抑制移植物抗宿主病的PKCθ的小分子抑制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105078998B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112118842A (zh) * | 2018-01-17 | 2020-12-22 | 明赛制药股份公司 | 用于癌症治疗的联合疗法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101296904A (zh) * | 2005-07-11 | 2008-10-29 | 德福根有限公司 | 作为激酶抑制剂的酰胺衍生物 |
-
2015
- 2015-08-05 CN CN201510471935.2A patent/CN105078998B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN105078998A (zh) | 2015-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Magrì et al. | High-dose vitamin C enhances cancer immunotherapy | |
Tettamanti et al. | Catch me if you can: how AML and its niche escape immunotherapy | |
Fan et al. | A dual PI3K/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy | |
Lv et al. | Immunotherapy: reshape the tumor immune microenvironment | |
Carniti et al. | Pharmacologic inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects | |
Venkatachalam et al. | Immune checkpoint inhibitors in prostate cancer | |
Linden et al. | Regulation of lymphocyte function by adenosine | |
Calì et al. | Tuning cancer fate: the unremitting role of host immunity | |
Norde et al. | PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation | |
Flores et al. | Lin− CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade | |
Kim et al. | Oxaliplatin regulates myeloid‐derived suppressor cell‐mediated immunosuppression via downregulation of nuclear factor‐κB signaling | |
Shindo et al. | MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner | |
Lai et al. | Local irradiation sensitized tumors to adoptive T cell therapy via enhancing the cross-priming, homing, and cytotoxicity of antigen-specific CD8 T cells | |
Magalhaes et al. | Facing the future: challenges and opportunities in adoptive T cell therapy in cancer | |
de Haart et al. | Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance | |
Hinterbrandner et al. | Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells | |
Wolf et al. | The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo | |
Davis et al. | Checkpoint inhibition in pediatric hematologic malignancies | |
CN109722437A (zh) | 一种通用型car-t细胞及其制备方法和用途 | |
CN109652378A (zh) | 一种功能增强的通用型car-t细胞及其制备方法和用途 | |
Nakasone et al. | Therapeutic benefits targeting B-cells in chronic graft-versus-host disease | |
Wang et al. | Memory T cells mediate cardiac allograft vasculopathy and are inactivated by anti-OX40L monoclonal antibody | |
Cohen et al. | TNFR2: The new Treg switch? | |
Wang et al. | Cholesterol-lowering intervention decreases mTOR complex 2 signaling and enhances antitumor immunity | |
Matsuoka et al. | Myeloid differentiation factor 88 signaling in donor T cells accelerates graft-versus-host disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190906 Address after: Room 411, Building 15, No. 8, Jinfeng Road, Suzhou High-tech Zone, Jiangsu Province Patentee after: Suzhou pharos Biological Medicine Technology Co.,Ltd. Address before: 200000, room 7, building 300, Lane 802, Jinxiu Road, Shanghai, Pudong New Area Patentee before: Fan Guohuang |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200706 Address after: Room 402, building 8, 760 xinjunhuan Road, Minhang District, Shanghai, 201100 Patentee after: Anmengde Pharmaceutical Technology (Shanghai) Co.,Ltd. Address before: Room 411, Building 15, No. 8, Jinfeng Road, Suzhou High-tech Zone, Jiangsu Province Patentee before: Suzhou pharos Biological Medicine Technology Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Room 402, building 8, 760 Xinjun Ring Road, Minhang District, Shanghai 201100 Patentee after: Aimeifei Biopharmaceutical Technology (Shanghai) Co.,Ltd. Address before: Room 402, building 8, 760 Xinjun Ring Road, Minhang District, Shanghai 201100 Patentee before: Anmengde Pharmaceutical Technology (Shanghai) Co.,Ltd. |